04:52 PM EDT, 06/11/2025 (MT Newswires) -- Intensity Therapeutics ( INTS ) intends to offer shares in an underwritten public offering, partly to fund a clinical trial for a breast cancer treatment.

Net proceeds will be used for the enrollment of patients and data readout in the Phase 2 clinical trial investigating INT230-6, an intratumoral cancer therapy, for early-stage, operable triple-negative breast cancer.

Funds will also be used for working capital and general corporate purposes, Intensity Therapeutics ( INTS ) said Wednesday in a statement.

Shares of the company fell 26% in after-hours trading.